Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, reports updates from the HORIZON study (NCT02963493), which is investigating the benefit of melflufen in combination with dexamethasone in relapsed/refractory multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).